Related references
Note: Only part of the references are listed.Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study
Seoyoung C. Kim et al.
AMERICAN JOURNAL OF MEDICINE (2015)
Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy
Ankita Modi et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women
J. Yu et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2015)
Improving adherence to and persistence with oral therapy of osteoporosis
M. L. Bianchi et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Cost and Consequences of Noncompliance to Oral Bisphosphonate Treatment
Debra F. Eisenberg et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2015)
Risk factors for fracture among current, persistent users of bisphosphonates
E. S. LeBlanc et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data
Andrea M. Burden et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2015)
Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review
Erik F. Eriksen et al.
BONE (2014)
Secular Trends in Hip Fractures Worldwide: Opposing Trends East Versus West
Ghada Ballane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Osteoporosis Prevention, Screening, and Treatment: A Review
Juliana M. Kling et al.
JOURNAL OF WOMENS HEALTH (2014)
Epidemiology of fractures in Iceland and secular trends in major osteoporotic fractures 1989-2008
K. Siggeirsdottir et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries
Z. Wang et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Clinician's Guide to Prevention and Treatment of Osteoporosis
F. Cosman et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases
Marsha A. Raebel et al.
MEDICAL CARE (2013)
Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice
D. Weycker et al.
OSTEOPOROSIS INTERNATIONAL (2013)
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women
J. Yates
OSTEOPOROSIS INTERNATIONAL (2013)
Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan
Y. -K. Soong et al.
OSTEOPOROSIS INTERNATIONAL (2013)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs-an analysis using national health databases
K. R. Olsen et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy
R. Lindsay et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group
M. Hiligsmann et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Primary non-adherence to bisphosphonates in an integrated healthcare setting
K. Reynolds et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan
Sally W. Wade et al.
BONE (2012)
Persistence and compliance of medications used in the treatment of osteoporosis - analysis using a large scale, representative, longitudinal German database
Volker Ziller et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)
Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence
John S. Sampalis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective
Steven Boonen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Bisphosphonates for Osteoporosis - Where Do We Go from Here?
Marcea Whitaker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adherence to osteoporosis medications amongst Singaporean patients
M. H. H. Cheen et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada
A. M. Burden et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA)
E. Landfeldt et al.
OSTEOPOROSIS INTERNATIONAL (2012)
GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates
P. Hadji et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg
J. D. Wark et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases
M. Pazianas et al.
OSTEOPOROSIS INTERNATIONAL (2012)
A systematic review of hip fracture incidence and probability of fracture worldwide
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway
Helene M. Devold et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Bisphosphonates: The first 40 years
R. Graham G. Russell
BONE (2011)
Alendronate Adherence and Its Impact on Hip-Fracture Risk in Patients With Established Osteoporosis in Taiwan
T-C Lin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study
Serge Ferrari et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2011)
Bone Turnover Markers and Bone Mineral Density Response With Risedronate Therapy: Relationship With Fracture Risk and Patient Adherence
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Which fractures are most attributable to osteoporosis?
Amy H. Warriner et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors
S. M. Cadarette et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims
R. Copher et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
The Complex Relation between Bisphosphonate Adherence and Fracture Reduction
Amanda R. Patrick et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis
I. Imaz et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates
Becky A. Briesacher et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
Predicting Risk of Osteoporotic Fracture in Men and Women in England and Wales: Prospective Derivation and Validation of QFractureScores
P. Mikosch
JOURNAL FUR MINERALSTOFFWECHSEL (2010)
Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women
Dana Bliuc et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Health Care Expenditures Associated With Skeletal Fractures Among Medicare Beneficiaries, 1999-2005
Meredith L. Kilgore et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures
O. Sheehy et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Excess mortality following hip fracture: a systematic epidemiological review
B. Abrahamsen et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women
Julie Blouin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Persistence of weekly alendronate: a real-world study in Croatia
Simeon Grazio et al.
CLINICAL RHEUMATOLOGY (2008)
Relationship Between Compliance and Persistence with Osteoporosis Medications and Fracture Risk in Primary Health Care in France: A Retrospective Case-Control Analysis
Francois-Emery Cotte et al.
CLINICAL THERAPEUTICS (2008)
Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures
Willemijn M. Meijer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Fracture outcomes related to persistence and compliance with oral bisphosphonates
Arlene M. Gallagher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate users
Jeffrey R. Curtis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Commentary: A revised clinician's guide to the prevention and treatment of osteoporosis
Bess Dawson-Hughes
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Adherence to bisphosphonate treatment by elderly women
Janneke Berecki-Gisolf et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2008)
Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks
N. D. Nguyen et al.
OSTEOPOROSIS INTERNATIONAL (2008)
FRAX™ and the assessment of fracture probability in men and women from the UK
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women
V. Rabenda et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Loss of treatment benefit due to low compliance with bisphosphonate therapy
F. J. A. Penning-van Beest et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Effects of raloxifene on fracture risk in postmenopausal women: The raloxifene use for the heart trial
Kristine E. Ensrud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies
Stuart L. Silverman et al.
SOUTHERN MEDICAL JOURNAL (2007)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills
Thomas W. Weiss et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
A systematic review of persistence and compliance with bisphosphonates for osteoporosis
J. A. Cramer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
Pierre D. Delmas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
Russel Burge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Risk of subsequent fracture after low-trauma fracture in men and women
Jacqueline R. Center et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Brand versus generic alendronate: Gastrointestinal effects measured by resource utilization
Hillel Halkin et al.
ANNALS OF PHARMACOTHERAPY (2007)
Reliability of medicaid claims versus medical record data - In a cost analysis of palivizumab
Julie Jacobson Vann et al.
PHARMACOECONOMICS (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study
S. de Lusignan et al.
OSTEOPOROSIS INTERNATIONAL (2006)
The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France
Joyce A. Cramer et al.
CLINICAL THERAPEUTICS (2006)
Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study
C. H. A. van den Boogaard et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases
Eamonn Brankin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population
KF Huybrechts et al.
BONE (2006)
Determinants of adherence to osteoporosis treatment in clinical practice
M. Rossini et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Systematic review: Bisphosphonates and osteonecrosis of the jaws
Sook-Bin Woo et al.
ANNALS OF INTERNAL MEDICINE (2006)
Incidence and causes for failure of treatment of women with proven osteoporosis
N Zafran et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
JA Cramer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women
RR Recker et al.
MAYO CLINIC PROCEEDINGS (2005)
Efficacy of risedronate on clinical vertebral fractures within six months
C Roux et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled
JA Clowes et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Compliance with drug therapies for the treatment and prevention of osteoporosis
JS McCombs et al.
MATURITAS (2004)
Seven years of treatment with risedronate in women with postmenopausal osteoporosis
DD Mellström et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
JJ Caro et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis
S Aki et al.
YONSEI MEDICAL JOURNAL (2003)
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience
OH Sorensen et al.
BONE (2003)
The economic cost of hip fractures among elderly women - A one-year, prospective, observational cohort study with matched-pair analysis
P Haentjens et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Hormone replacement therapy and incidence of acute myocardial infarction -: A population-based nested case-control study
C Varas-Lorenzo et al.
CIRCULATION (2000)
Share Paper
